AI-generated summary
The authors report a randomized split-body trial comparing a 311-nm titanium:sapphire laser with a 308-nm excimer laser for localized vitiligo, with 21 patients and 74 paired lesions. They found the difference in repigmentation between the two lasers to be within the prespecified non-inferiority margin, and no serious adverse events were noted in either group.
- Participants
- 21
- Who or what was studied
- Patients with stable localized vitiligo enrolled between June 2016 and May 2017, with 74 paired lesions in 21 patients
- Wavelengths
- 311, 308 nm
- Limits stated in the abstract
- The abstract reports a small sample of 21 patients and does not describe long-term follow-up or the certainty of the findings beyond the single non-inferiority comparison.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 311 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Randomized controlled trial, Confidence interval, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.